Literature DB >> 20101035

Elevated CSF N-acetylaspartylglutamate in patients with free sialic acid storage diseases.

F Mochel1, U F H Engelke, J Barritault, B Yang, N H McNeill, J N Thompson, A Vanderver, N I Wolf, M A Willemsen, F W Verheijen, F Seguin, R A Wevers, R Schiffmann.   

Abstract

OBJECTIVE: To investigate body fluids of patients with undiagnosed leukodystrophies using in vitro (1)H-NMR spectroscopy (H-NMRS).
METHODS: We conducted a cross-sectional study using high-resolution in vitro H-NMRS on CSF and urine samples.
RESULTS: We found a significant increase of free sialic acid in CSF or urine in 6 of 41 patients presenting with hypomyelination of unknown etiology. Molecular genetic testing revealed pathogenic mutations in the SLC17A5 gene in all 6 patients. H-NMRS revealed an increase of N-acetylaspartylglutamate in the CSF of all patients with SLC17A5 mutation (range 13-114 micromol/L, reference <12 micromol/L).
CONCLUSION: In patients with undiagnosed leukodystrophies, increased free sialic acid in CSF or urine is a marker for free sialic acid storage disorder and facilitates the identification of the underlying genetic defect. Because increase of N-acetylaspartylglutamate in CSF has been observed in other hypomyelinating disorders, it can be viewed as a marker of a subgroup of hypomyelinating disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101035      PMCID: PMC3122303          DOI: 10.1212/WNL.0b013e3181cbcdc4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

2.  N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease.

Authors:  Alessandro P Burlina; Vanni Ferrari; Alberto B Burlina; Mario Ermani; Odile Boespflug-Tanguy; Enrico Bertini
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

3.  A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases.

Authors:  F W Verheijen; E Verbeek; N Aula; C E Beerens; A C Havelaar; M Joosse; L Peltonen; P Aula; H Galjaard; P J van der Spek; G M Mancini
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

4.  N-acetylaspartylglutamate in Canavan disease: an adverse effector?

Authors:  A P Burlina; V Ferrari; P Divry; W Gradowska; C Jakobs; M J Bennett; A C Sewell; C Dionisi-Vici; A B Burlina
Journal:  Eur J Pediatr       Date:  1999-05       Impact factor: 3.183

5.  Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF.

Authors:  N I Wolf; M A A P Willemsen; U F Engelke; M S van der Knaap; P J W Pouwels; I Harting; J Zschocke; E A Sistermans; D Rating; R A Wevers
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

6.  Increased level of N-acetylaspartylglutamate (NAAG) in the CSF of a patient with Pelizaeus-Merzbacher-like disease due to mutation in the GJA12 gene.

Authors:  Stefano Sartori; Alberto B Burlina; Leonardo Salviati; Eva Trevisson; Irene Toldo; Anna Maria Laverda; Alessandro P Burlina
Journal:  Eur J Paediatr Neurol       Date:  2007-09-18       Impact factor: 3.140

7.  Cerebellar ataxia with elevated cerebrospinal free sialic acid (CAFSA).

Authors:  F Mochel; F Sedel; A Vanderver; U F H Engelke; J Barritault; B Z Yang; B Kulkarni; D R Adams; F Clot; J H Ding; C R Kaneski; F W Verheijen; B W Smits; F Seguin; A Brice; M T Vanier; M Huizing; R Schiffmann; A Durr; R A Wevers
Journal:  Brain       Date:  2009-01-19       Impact factor: 13.501

8.  Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia.

Authors:  L Passani; S Elkabes; J T Coyle
Journal:  Brain Res       Date:  1998-05-25       Impact factor: 3.252

9.  Free sialic acid storage disease without sialuria.

Authors:  Fanny Mochel; Bingzhi Yang; Julie Barritault; Jerry N Thompson; Udo F H Engelke; Nathan H McNeill; William S Benko; Christine R Kaneski; David R Adams; Maria Tsokos; Mones Abu-Asab; Marjan Huizing; Francois Seguin; Ron A Wevers; Jiahuan Ding; Frans W Verheijen; Raphael Schiffmann
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

10.  The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes.

Authors:  Karolina Kolodziejczyk; Nicola B Hamilton; Anna Wade; Ragnhildur Káradóttir; David Attwell
Journal:  Brain       Date:  2009-04-21       Impact factor: 13.501

  10 in total
  5 in total

1.  Infantile Sialic Acid Storage Disease: Two Unrelated Inuit Cases Homozygous for a Common Novel SLC17A5 Mutation.

Authors:  Matthew A Lines; C Anthony Rupar; Jack W Rip; Berivan Baskin; Peter N Ray; Robert A Hegele; David Grynspan; Jean Michaud; Michael T Geraghty
Journal:  JIMD Rep       Date:  2013-07-31

2.  N-acetylaspartylglutamate synthetase II synthesizes N-acetylaspartylglutamylglutamate.

Authors:  Julia Lodder-Gadaczek; Ivonne Becker; Volkmar Gieselmann; Lihua Wang-Eckhardt; Matthias Eckhardt
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

3.  Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases.

Authors:  Fanny Mochel; Nadège Boildieu; Julie Barritault; Catherine Sarret; Eleonore Eymard-Pierre; François Seguin; Raphael Schiffmann; Odile Boespflug-Tanguy
Journal:  Biochim Biophys Acta       Date:  2010-07-13

Review 4.  Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.

Authors:  Shreyas Bhat; Ali El-Kasaby; Michael Freissmuth; Sonja Sucic
Journal:  Pharmacol Ther       Date:  2020-12-10       Impact factor: 12.310

5.  Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).

Authors:  Miriam Sindelar; Jonathan P Dyke; Ruba S Deeb; Dolan Sondhi; Stephen M Kaminsky; Barry E Kosofsky; Douglas J Ballon; Ronald G Crystal; Steven S Gross
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.